There has been a lot of buzz in the psychedelic space the last couple years. With this stock posting phase 3 results in Q4 I wonder if this is a buyout play with big pharma? They seem to be putting people with pharma backgrounds in key leaderships spots within the company. What do you think?
Leave a Reply